阿斯利康口服SERD新药Etcamah一线乳腺癌III期SERENA-4未达主要终点，但属上周五旧闻且早已被低预期消化

AstraZeneca’s newly approved pill fails frontline breast cancer study | BioPharma Dive
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
AstraZeneca’s newly approved pill fails frontline breast cancer study
Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
Published Sept. 14, 2026
Delilah Alvarado
Reporter
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Add us on Google
AstraZeneca office in San Francisco, Calif., on Nov. 15, 2020.
Alamy
A newly approved drug from AstraZeneca has failed a major trial that could have supported broader use of the therapy in frontline breast cancer.
According to AstraZeneca, a combination of its therapy Etcamah and a commonly used medication
failed to significantly delay disease progression
compared to that standard medicine and hormone therapy in people newly diagnosed with advanced ER-positive, HER2-negative breast cancer. The company didn’t provide specifics in its statement Friday, but said that treatment was associated with a “numerical improvement” in progression-free survival that didn’t reach statistical significance.
Detailed data will be shared “in due course,” AstraZeneca said.
Etcamah is part of a class of oral medicines called selective estrogen receptor degraders, or SERDs. These treatments are being developed as alternatives to the decades-old injectable breast cancer therapy fulvestrant. A few have recently gotten to market, and another could be cleared later this year.
Drug companies, however, have struggled to prove that oral SERDs will become the broadly used medicines they’d originally anticipated. The benefits have been most pronounced among a subset of breast cancer patients with “ESR1” mutations that help tumors develop resistance to treatment.
AstraZeneca has been hoping for better with Etcamah. The drug won an
accelerated approval
earlier this month in a novel setting, where treatment is recommended as a part of first-line care once an ESR1 mutation is detected by an FDA-approved test. That clearance supported expectations from AstraZeneca executives that the therapy might eventually rake in
$5 billion annually
, making Etcamah a key part of the company’s plans to
reach $80 billion in yearly sales
by 2030.
The study AstraZeneca reported on Friday, “SERENA-4,” was meant to be another step forward in that plan, as it evaluated Etcamah as part of a standard frontline regimen. But expectations dimmed after another oral SERD
from Roche called giredestrant failed a study in a similar setting
. SERENA-4 was a “high-risk, high-reward” study, wrote Leerink Partners analyst Andrew Berens. He’d given the study a 20% probability of succeeding.
AstraZeneca is awaiting the results of another study important to its future. Called “AVANZAR,” that trial is testing another one of its cancer drugs, Datroway, in first-line non-small cell lung cancer. In a recent research note, though, RBC Capital Markets analyst Trung Huynh argued that AstraZeneca could still hit its revenue target even if that trial is unsuccessful.
Etcamah could still succeed elsewhere, too. A pair of ongoing trials,
CAMBRIA-1
and
CAMBRIA-2
, are testing the therapy in the “adjuvant” setting after surgery.
Add us on Google
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Filed Under:
Pharma,
Clinical Trials
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive
//
Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner •
Updated Aug. 4, 2026
Permission granted by Nasdaq, Inc. / Vanja Savic
Deep Dive
//
Emerging biotech
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
By Gwendolyn Wu •
April 28, 2026
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
Cellsonics to auction off high-end research and development instruments via Silicon Valley Dis…
From Silicon Valley Disposition
September 10, 2026
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New B…
From Schrödinger, Inc.
September 09, 2026
FDA Approves Tablet Form of Zanubrutinib for All Approved Indications
From BeOne Medicines
September 09, 2026
ACTO Achieves Veeva Gold Product Partner Status, Following a Nearly Decade-Long Collaboration …
From ACTO
September 02, 2026
Editors' picks
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive
//
Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner •
Updated Aug. 4, 2026
Permission granted by Nasdaq, Inc. / Vanja Savic
Deep Dive
//
Emerging biotech
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
By Gwendolyn Wu •
April 28, 2026
Latest in Clinical Trials
Tyra disappoints investors with bladder cancer data
By Jonathan Gardner
Novartis RNA drug falls short in rare muscle disease study
By Jacob Bell
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
By Ben Fidler
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
By Jonathan Gardner
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell